Quotient Clinical showcases ‘Gold Standard’ Human ADME studies and applications at ISSX/JSSX 2014

Quotient Clinical, the Translational Pharmaceutics Company, will present a symposium and three poster publications at the forthcoming 19th North American ISSX Meeting / 29th JSSX Meeting (ISSX/JSSX 2014) from October 19^th to 23rd in San Francisco, USA.

The symposium entitled “Defining a ‘Gold standard’ for establishing intravenous pharmacokinetics, human mass balance and metabolism data from a single integrated study and a single regulatory submission” will focus on the delivery and conduct of human ¹⁴C-enabled metabolism and pharmacokinetic studies intended to support drug registration.

The poster publications describe recent advancements in the design of integrated clinical programs to generate pivotal pharmacokinetic and metabolism data addressing key development and regulatory requirements.

Details of the symposium and poster presentations are:

Defining a ‘Gold standard’ for establishing intravenous pharmacokinetics, human mass balance and metabolism data from a single integrated study and a single regulatory submission
Thursday, October 23^rd, 7:30 – 8:30am in the Imperial Ballroom

Flexible strategies for the conduct of human metabolism studies with oncology molecules
Session 4, Tuesday, October 21^st, 5.30 – 7:00pm
Abstract Id: 33582, Poster No P344

An integrated strategy to determine the absorption, distribution, metabolism, and excretion, and the absolute bioavailability of Bevenopran (CB-5945) in healthy male subjects
Session 4, Tuesday, October 21^st, 5.30 – 7:00pm
Abstract Id: 33615, Poster No P326

Intravenous studies in man: Teasing apart absorption and clearance drivers of pharmacokinetic variability and dose and time dependent non-linearity
Session 4, Tuesday, October 21^st, 5.30 – 7:00pm
Abstract Id: 33880, Poster No P382

Quotient Clinical will be located at exhibition booth #312.  Should you wish to arrange a meeting, please email [email protected]